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Abstract
The ErbB family of receptor tyrosine kinases plays important roles in cell proliferation, differentiation,
and apoptosis. Recent structural studies of these receptors have demonstrated dramatic
conformational effects that are critical to their ligand binding and activation, and have shown that
these receptors provide levels of control beyond the classic dimerization/activation mechanism.
These results indicate that this class of receptors has evolved subtle regulatory mechanisms via
genetic and protein structural changes to influence their effects on cell behaviors.
Introduction and context
Receptor tyrosine kinases pass information from the
exterior to the interior of cells. Binding of a ligand to an
extracellular domain of the receptor triggers activation of
the kinase domain at the cytoplasmic surface of the
plasma membrane, resulting in phosphorylation of
tyrosine residues of the receptor’s cytoplasmic sequences
[1]. The classic mechanism for this transition is the
dimerization of receptor molecules induced by ligand
binding, which juxtaposes cytoplasmic domains to
facilitate a transphosphorylation by the kinase domains
between the adjacent receptors [2]. The phosphorylated
tyrosines then act to recruit cytoplasmic proteins, such as
adaptors, docking proteins, and enzymes, which initiate
downstream signaling pathways that control cellular
behaviors [3]. The prototype for development of this
mechanism has been the epidermal growth factor (EGF)
receptor and its family members, known as ErbBs.
However, recent studies of this family have shown that
their signaling mechanisms are much more complex and
subtle than a simple dimerization model.
The ErbB family consists of four members that share
a common domain structure consisting of four extra-
cellular domains, a transmembrane domain, a
juxtamembrane cytoplasmic domain, a kinase domain,
and a C-terminal tail, which contains most of the
phosphorylated tyrosines [3] (Figure 1). Although family
members ErbB1 and ErbB4 can be phosphorylated
directly after ligand binding and homodimerization,
ErbB2 and ErbB3 cannot [4]. No soluble high-affinity
ligand has been demonstrated for ErbB2 [4], and ErbB3
has an inactive kinase domain [5]. Thus, ErbB2 has been
proposed to act primarily as a co-receptor through
heterodimerization with the other three receptors and
activation via their ligands [6]. In contrast, ErbB3 serves
as a docking protein that is phosphorylated by the other
family members. The ErbB2/ErbB3 pair is particularly
potent for activating proliferation responses [7].
Major recent advances
A role for conformational effects in ligand binding to the
ErbBs has been shown by crystallographic studies of their
extracellular domain structures [8]. ErbB1, ErbB3, and
ErbB4 were demonstrated to be in an intramolecular
‘tethered’ conformation in the absence of ligand, in
which extracellular domains 2 and 4 are linked [9-11]
(Figure 1). In contrast, these receptors in the presence of
ligand are in an ‘extended’ conformation in which a loop
in domain 2 is freed and serves as a coupling site for the
Page 1 of 4
(page number not for citation purposes)
Published: 28 September 2009
© 2009 Biology Reports Ltd
for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License
(http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,association of two receptor molecules in a dimer [12]
(Figure 1). ErbB2 exhibits a different structure, as it is in
an extended conformation in the absence of ligand, with
its domain 2 loop available for interaction with the other
ErbBs [13]. These crystallographic studies are supported
by small x-ray scattering studies of the extracellular
regions of ErbB1, ErbB2, and ErbB3 [14]. Since the
ligand-binding site of the ErbBs is closed in the extended
conformation, these results can explain the failure to find
a soluble ErbB2 ligand. However, it should be noted that
the ErbBs must exhibit considerable conformational
fluctuations and flexibility as receptor dimers, such as
the ErbB2/ErbB3 couple, can be formed even in the
absence of ligand, although ligand is required for
phosphorylation [15].
The mechanism of phosphorylation has been investi-
gated by crystallographic studies and mutational ana-
lyses of the cytoplasmic domains of the EGF receptor.
Surprisingly, these results showed an asymmetric
interaction between the two kinase domains of the
coupled receptors, in which the large lobe of one kinase
domain (donor) associates with the small lobe of the
other receptor (acceptor) (Figure 1), thus stabilizing the
active conformation of the small lobe [16]. This
activation mechanism resembles that of cyclin-depen-
dent kinases, applies to both homodimers and hetero-
dimers of ErbBs, and differs from that of most other
receptor tyrosine kinases, such as the insulin receptor
[16,17]. The ability of the ErbB kinase domains to serve
as both activators and transducers of the ligand signal
provides a powerful discriminatory mechanism for the
regulation of signaling through these receptors.
Despite extensive studies, the exact relationship between
EGF binding and EGF receptor dimerization has
remained elusive. Recent work has shown that binding
is positively linked to dimerization in unphosphorylated
receptors but that the linkage is lost with receptor
autophosphorylation [18]. In addition, these studies
Figure 1. A general model for the activation of members of the ErbB family, illustrating the case of the ErbB2-ErbB3 heterodimer
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ErbB monomer conformation is depicted for the unique ErbB2 extended conformation and for the tethered ErbB3 monomer, also representing the
conformation of ErbB1 and ErbB4. Ligand (L) is labeled in red, and the curved arrow provides a visual aid for the direction of conformational change from the
tethered to the extended form in the presence of ligand. Extracellular domains are colored in shades of orange (ErbB2) and blue (ErbB3) and are numbered
for further aid in visualizing the conformational changes. The transmembrane domain is in pale blue. Intracellular subdomains are labeled, and within the
cytoplasmic tail, empty circles represent nonphosphorylated tyrosine residues and red circles represent tyrosine phosphorylation. An active ErbB2-ErbB3
heterodimer is also depicted and portrays the alignment of the extracellular dimerization domain, the asymmetric orientation of the kinase domains, and the
role of the juxtamembrane region in promoting this orientation. How ErbB2 becomes phosphorylated in this specific dimer is not clear at this time.
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cooperativity, in which ligand binding to the first subunit
of the dimer decreases the affinity with which ligand
binds to the second subunit in the dimer [19]. Signifi-
cantly, this cooperativity is dependent on the presence of
the intracellular juxtamembrane domain of the receptor
[18]. These findings indicate that this domain can
influence ligand binding and cause a type of inside-out
signaling, providing further evidence that the ErbBs have
evolved very subtle and sophisticated regulatory mechan-
isms for coupling ligand binding and phosphorylation.
Importantly, the juxtamembrane domain of the EGF
receptor has also been shown to be involved in receptor
activation [20,21]. Crystal structures of EGF receptor
dimers that include the juxtamembrane region show that
theC-terminalhalfofthejuxtamembranedomain(JM-B)
‘latches’ the C-lobe of the donor kinase domain to the N-
lobe of the acceptor domain (Figure 1), which stabilizes
the dimer and promotes the allosteric activation of the
acceptortyrosinekinasedomain.Inthesymmetricdimer,
which is inactive, this interaction is prevented by the
cytoplasmic tails of the receptors. Ligand engagement by
the extracellular domains stabilizes the formation of the
juxtamembrane domain interaction with the kinase
domain, which in turn stabilizes the kinase domain
dimer, a type of outside-in signaling.
Future directions
Although the conformational changes and preferences
described here apply specifically to the ErbBs, it will be
interesting to find out whether they are also exhibited in
other receptors. Moreover, it remains to be seen how
these conformational effects alter specific downstream
signaling pathways. A continuing question for ErbB
phosphorylation is how the activated kinase domain
interacts with and phosphorylates particular residues of
the cytoplasmic tail region to specify different pathways.
One puzzle remaining for the ErbB2-ErbB3 heterodimer
shown in Figure 1 is how the ErbB2 is phosphorylated
since ErbB3 is ‘kinase dead’. Is this due to a ‘true
autophosphorylation’ or to the formation of higher-
order multimers, or to some other mechanism yet
undiscovered? Finally, it is clear from the combined
results of these efforts that the receptor molecules must
be considered as a complete dynamic package, in which
all of the domains, including the transmembrane
domain, may contribute to their functions.
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